

"Bind-Encapsulate-Destroy"

NanoViricides Incorporated

Stock Symbol:
NNVC
(NYSE American)

# Nanoviricides, Inc.

## A Clinical Stage Company

## Revolutionizing Antiviral Therapeutics

## Platform Technology with Broad and Rich Pipeline

Corporate Presentation as of December, 2023


Presented by:

Anil R. Diwan, PhD

President & Exec. Chairman

adiwan@nanoviricides.com

# Disclosure Statement:

NanoViricides, Inc. is a NYSE-American listed publicly traded company (NNVC). This is not an offering memorandum and should not be construed as such. This presentation is provided as a non-confidential document for informational purposes only.

NanoViricides, Inc.(www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials as therapeutics against a number of different viruses. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. All of our drug candidates are based on broad and exclusive worldwide licenses in perpetuity from TheraCour Pharma, Inc. for the development of drugs to combat viral infections of Human Coronaviruses, Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Herpes Simplex Viruses (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu viruses, Dengue viruses, Ebola/Marburg viruses, Japanese Encephalitis virus, viruses causing viral Conjunctivitis (a disease of the eye). The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

This document contains forward-looking statements that reflect the current expectation of NanoViricides, Inc. (the "Company) regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements.

The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.

Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

# NanoViricides : At a Key Inflection Point; Ready for Take-off

- **Clinical Stage Company - NV-387, First Drug in Phase 1 Clinical Trials Nearing Completion**
  - Excellent Safety in Humans - No Adverse Events to Date
- **Oral Syrup for Pediatrics, Oral Gummies (No swallowing) for Seniors and Adults**
- **Triple-demic in Our Cross-hairs : Coronaviruses including COVID, RSV, and Many Other Respiratory Pathogens Treatable with NV-387 !**
- **NV-HHV-1, for Treatment of Shingles, is Waiting in the Wings to Engage into IND**
- **NanoViricides Fully Owns Its cGMP-compliant Manufacturing Facility**
  - Supplying Clinical Drug Products
  - Supporting Initial Commercialization with Revenue Generation
- **Multiple Drug Programs with Large Market Sizes based on Platform Technology will Continue to Fuel Future Growth**
  - Clinical Asset: NV-387 (Multiple Respiratory Infections, MPox, Smallpox)
  - Clinical-Ready Asset: NV-HHV-1 (Shingles)
  - Over forty Additional Indications at Various Pre-Clinical Effectiveness Stages

# How and Why Are NanoViricides Better Than Current Antiviral Drugs? Better by Design!

- A Nanoviricide® is a Chemical Nanomachine that "Finds, Binds, & Engulfs" the Virus Particle so the Virus Cannot Reinfect Other Cells -
  Like a "Venus Flytrap" for Viruses

- It Does Not Require a Competent Immune System in the Patient, Unlike Most Other Approaches (e.g. Antibodies), because the Nanoviricide Directly Attacks the Virus Particle and Completes the Task of Dismantling It

- Virus Escape by Mutation/Variants is Highly Unlikely, because
  the Landing Site the Virus Uses Doesn't Change Even as the Virus Evolves
  and the Nanoviricide Copies the Receptor (Landing) Site
  In Contrast, Other Antivirals Are Specific to Features of the Virus which Change with Mutations, and therefore the Virus Escapes those Drugs Readily

- Excellent Human Safety Indicates Nanoviricides Can Be Used for Everyone:
  Pediatrics, Senior Citizens, Immune-Compromised Patients, Normal Adults -
  Distinguishing Our Platform from Other Antivirals that Have Significant Limitations on Patient Eligibility



# Revolutionizing Treatment of Viral Infections Just As Antibiotics Revolutionized Bacterial Infections

- **One Drug, NV-387, is Effective Against Many Respiratory Viruses**
  - Likely Most Effective Drug Against Coronaviruses - SARS-CoV-2 included
  - Most Effective Against RSV - No Current Treatment Except Ribavirin which is only used as Last Resort Due to Toxicity (Hemotoxic, Multi-Organ Failures)
- **Phase 1 Clinical Trial Nearing Completion - Extremely Safe - No Adverse Events**
- **NV-387 is Expected to be Effective Against Many Other Viruses**
  - Highly Effective Against Mpox, Smallpox (model virus Animal Study) - Demonstrated
  - Over 90% of Human Pathogenic Viruses Use Sulfated-Proteoglycans (S-PG) for Attachment
  - NV-387 Copies the Receptor Site, S-PG Feature that is Used by Many Virus Families
  - NV-387 "Looks Like" a biological Cell Membrane that Carries S-PG Mimetics on its Surface
- **NV-387 Effective Even as Viruses Mutate because They Still Use S-PG**
- **NanoViricides Platform Technology - Prove for One Drug, Prove for Many**
  - Developing Additional Drugs Against Other Common Virus Attachment Motifs
  - Such Drugs Expected Be Effective Against Any Emergent or Novel Viruses
  - Enabling a New Paradigm for Pandemic Preparedness

# Current Clinical Trial and Clinical-Ready Assets

# NanoViricides Drug Products : Clinical Asset, NV-CoV-2 (NV-387) Phase I a/Ib Clinical Trial Near Completion

- **Orally Bio-available Drug; Two Oral Formulations in Clinical Trial**
  - NV-CoV-2 Oral Syrup (OS) - Titrate per Body Weight (Children)
  - NV-CoV-2 Oral Gummies (OG) - Fixed Dose Form
  - Oral Gummies to Overcome the Issue of Swallowing Difficulty
- **Safety and Tolerability; Human PK in both Single Dose (Phase 1a) and Multiple Dose (Phase 1b) Regimens**
- **36 Healthy Volunteers; 3 Dose Levels; 2 Formulations (6 per Cohort)**
- **No Adverse Events or Serious Adverse Events in 26 Completed of 36**
- **Excellent Safety and Tolerability To Date**
- **Enables Use of the Drug for All Patient Populations from Pediatrics, Seniors, Normal Adults, to Immune-Compromised Patients**
- **In Contrast, Current COVID Drugs Have Severe Limitations on Eligible Patients**
- **Solution for Injection, Infusion and Inhalation for the Treatment of Hospitalized Patients formulation is also available**

# NanoViricides Drug Products : Clinical Asset, NV-CoV-2 (NV-387) Further Development Pathway - After Phase I

- **Phase II or Phase II/III Clinical Trials for Different Antiviral Indications:**
- **1. NV-CoV-2: Treatment of COVID and certain cases of Long COVID**
  - API NV-387, Oral Syrup and Oral Gummies Drug Product Formulations
  - Broad-Spectrum, Pan-coronavirus Drug - “Resistance is Futile"
  - Highly Effective and Extremely Safe in Pre-Clinical Models
  - Excellent PK in monkey and rodent animal models
  - Also NV-CoV-2 Solution for Injection, Infusion, and Inhalation for Hospitalized Cases
- **2. Phase 2/3: NV-387 for the Treatment of RSV Infection in Adults**
- **3. Phase 2/3: NV-387 for the Treatment of RSV Infection in Pediatric Patients**
- **4. Advance NV-387 for Smallpox/Mpox If Non-Dilutive Funding is Available**
- **5. NV-387 for the Treatment of Other Respiratory Infections**

# NanoViricides Drug Products : Clinical-Ready Assets
# NV-HHV-1 (Shingles) and NV-387-g-R (Broad-Spectrum Cure)

- **NV-HHV-1: Skin Cream for Treatment of Shingles Rash**
  - IND-enabling Studies Completed
- **NV-387-g-R: Encapsulates Remdesivir within NV-387; Eligible for Phase II**
  - Extremely Broad-Spectrum Antiviral, like Antibiotics for Bacteria!
  - Substantially Improves Remdesivir PK/PD Profile
  - Enables Synergistic Drug Action with NV-387 and Remdesivir
  - Blocks Both (i) Re-infection & (ii) Replication Parts of Virus Life Cycle
- **Expect Complete Cure of Many Viruses Against Which Both NV-387 and Remdesivir are Individually Effective in vitro**
  - Remdesivir is Highly Effective in Cell Culture and Model Studies, But Has Poor Effectiveness in Clinical Trials and in Real World
  - Remdesivir is Readily Metabolized in the Bloodstream, Resulting in this Dichotomy
  - NV-387 Protects Remdesivir and is Expected to Improve Clinical Outcomes
  - NV-387 Itself Possesses Excellent Broad-Spectrum Antiviral Activity

# NanoViricides Technology Platform, Technology Assets and Intellectual Property

# NanoViricides ENABLER Platform Technology Asset: NanoViricides Technology Platform for Drug Development

- **Build Drugs that Attack Virus Particles by Mimicking Attachment Factors Commonly Used by Many Virus Families (Platform Modality #1)**
  - NV-387 Mimicking S-PG Used by >90% Human Pathogens
  - NV-x-458 Mimicking Sialyl-GP Used by Influenzas and Many Other Pathogens
  - Other Nanoviricides Against Additional Common Motifs in Development
- **Build Drugs that Attack Virus Particles and Virus-Infected Cells while Sparing Uninfected Cells by Mimicking Specific Receptors Used by a Single Virus Family or Virus (i.e. Mimicking "Cognate Receptors") (Platform Modality #2)**
  - Infected Cells Exhibit Viral Glycoproteins and Viruses on Their Surface
  - Specific Site-Directed Ligands Covalently Attached to Nanoviricide backbone for Binding to Viral Surface Glycoproteins
  - Example: NV-HHV-1 Mimicking Herpesvirus-Entry-Mediator (HVEM) is Effective Against VZV (Shingles, Chickenpox), HSV-1, HSV-2
  - Example: NV-HIV-1 Mimicking CD4 Effective Against All HIV Variants
- **Drug Escaping Virus Variant Generation is Highly Unlikely**

# NanoViricides Technology Platform Enabling Expanding Pipeline: Encapsulation of Another Drug Into a Nanoviricide - Potential Cures

- Complete Cure for Non-Latency Viruses
- A nanoviricide Can Hold in Its "Belly" and Deliver to Infected Cells, A Guest Drug
- The main Nanoviricide Blocks Re-Infection by Virus of Another Cell, and the Encapsulated Guest Drug Blocks Replication of Virus Inside a Cell
- Potentially Curing the Viral Infection

- Examples : NV-387-g-R, NV-387-m-T, NV-387-g-Ribvp, Others
- Published : NV-387-g-R ->
  - Encapsulation in NV-387 Improves the Availability and Lifetime of Remdesivir
  - Significantly Reduces Loss to Metabolism
  - Also Makes an Oral Drug Possible (NV-387-g-R is Orally Effective)
- This We Call NanoViricides Platform Modality #3



# NanoViricides ENABLER Platform Technology Asset: Cures Enabled while Providing Drug Lifecycle Extension and Drug Rescue by Encapsulation into a Nanoviricide

- **The Nanoviricides Technology Platform is Proven to be Capable of Encapsulating and Protecting APIs Improving their PK/PD and Bioactivity, Enabling Long Acting Acute Timeframe (~ 24 - 72 hours, Tailorable) and Making Oral Drug Administration Possible (Platform Modality #3)**
- **Multiple Mechanisms of Action Enabled Simultaneously**
- **Potential Cures for Non-Latency Viruses by Blocking Complete Virus Lifecycle**
  - Escape Variant Generation Highly Unlikely (Multi-Modal Mechanism of Action)
  - Example: NV-387 Blocking Re-Infection Cycle; A Guest Drug Blocking Replication Cycle
  - Examples: NV-387-g-R, NV-387-g-Ribvp, NV-387-m-Tecovirimat
- **Potential Cures for Latency Producing Viruses by Employing Multiple Mechanisms**
  - Example: NV-HHV-1 Encapsulating Another Anti-Herpesvirus Drug such as a replication inhibitors, maturation inhibitor, assembly inhibitors, etc. against herpesviruses
  - Maximize Effectiveness and Minimize Recurrences with Eventual Clearance/Cure
- **Rescue Drug Candidates that Do Not Fit Lipinski Criteria**
  - Many antiviral agents are highly hydrophobic, and are dropped during pre-clinical studies
- **Applications: Pandemic Preparedness; Biodefense, Highly Varying Viruses, Others**

# NanoViricides Technology Differentiation

| | Nanoviricide Drug | Antibodies | Other Drugs | Vaccines |
|---|---|---|---|---|
| Mechanism | Re-Infection Inhibition | Neutralization | Replication Inhibition | Antibodies Generation |
| Therapeutic Post-Infection? | **Yes** | **Yes** | **Yes** | **No** |
| **Viral Resistance** | **Unlikely** | **Rapidly** | **Eventually** | **Rapidly** |
| **Cure Possible for Non-Latency Viruses?** | **Yes** | **No** | **No** | **No** |
| **Broad Spectrum?** | **Yes** | **No** | **No/Maybe** | **No** |
| **Immune-Compromised Patients?** | **Yes** | **No/Maybe** | **Yes** | **No** |
| **Oral Dosing?** | **Yes** | **No** | **Yes/Maybe** | **No/Maybe** |
| **Infrequent Dosing?** | **Yes** | **No** | **No** | **Yes** |
| **Easy Compliance** | **Yes** | **No** | **No** | **No** |
| **No Need for Infusion** | **Yes** | **No** | **Yes** | **Yes** |
| **No or Minimal Side Effects** | **Yes** | **No** | **No** | **No** (Due to Large Numbers) |
| **Safe** (Allergy, Mutagen, Immunogen, Genotox) | **Yes** | **No** (Immune Reactions) | **No** (Often Mutagenic) | **No** (Immune Reactions, Allergy) |
| Storage and Supply Chain Conditions | **RT, 2-8°C** | **2-8°C** | **RT** | **-20°C** |
| Can Encapsulate Another API | **Yes** | **No** | **No** | **No** |

# About NanoViricides, Inc. Intellectual Property

- **Licensed Verticals of Programs from TheraCour Pharma, Inc. for Antiviral Drug Development Using the Unique TheraCour Polymeric Micelle Technology**
  - Licenses are for Vertical Areas - Treatment of Infections by Licensed Viruses
  - Not Limited to Specific Drug Candidates, but Cover All Current and Future Drug Candidates and Patents that Exist or May Result with the Undertaken R&D for Licensed Viruses
  - Exclusive, Sub-Licensable, Covering All International Territories
- **Intellectual Property is Fully Protected Under Several Patents**
  - Fundamental International PCT Patents Applied 2006, 2007
  - Resulted in Worldwide Issuances Covering Broad Claims for Fundamental Structure, Composition, Manufacture, and Methods of Use
  - New Specific International PCT Patents Applied for COVID Drugs in 2020 and 2021
    - Entering National Phase Now
  - Additional Patents Will be Filed as Drugs Move into the Clinical Stage
  - All Applicable Patents are Encompassed Under the Licenses from TheraCour Pharma
- **Nanoviricides Polymeric Micelle Compositions, as well as Certain Antiviral Ligands, Guest APIs and Pro-drugs, Formulations, Methods of Administration etc. Are Patented or Patent-Eligible**

# NanoViricides Value Proposition

# NanoViricides Value Proposition

- Have Sufficient Funds to Support the Phase 1a/1b Clinical Trial of NV-CoV-2 Drug and Filing of Phase 2 Clinical Trial Application
- Own cGMP-Compliant Manufacturing Facility Assets estimated at Replacement Value in excess of $25 M
- No Debt or Mortgage
- Non-Dilutive Funding for Bioterrorism & Pandemic Preparedness Programs is Possible for Smallpox, Pandemic Preparedness Platform, Other
- Successful Progress of NV-387 in Clinical Trials Towards First Regulatory Approval
- NV-387 Regulatory Approvals for Additional Indications in the Near Future
- Additional Drugs (NV-HHV-1, NV-387-g-R, Drugs to Treat HSV-1, HSV-2) Successfully Progress through Regulatory Pathway
- Revolutionary Platform Technology to Feed Growth for Many Years into the Future

# Why Is It Important that NanoViricides Designed & Owns Its Own cGMP-Capable Manufacturing Capability?

Multi-Kg Scale cGMP-Compliant Manufacturing Facility

- Eliminate CMO Risks; Minimize Time & Costs of Drug Products for Phase 1, 2, & 3 Clinical Trials
- Manufacture Commercial Drug Products to Enable Early Revenues from Rapid Market Entry
- Protect Proprietary Technology & Intellectual Property

- Nanomedicines Characterization Facility
- Virology BSL-2 Certified Lab
- Rapid Transfer and Process Scale-Up from Lab Bench to cGMP-Compliant Manufacture
- Highly Customizable & Flexible Manufacturing Capability - Active Ingredient to Finished Drug Product
- Oral Syrup, Oral Gummies, Skin Creams, Eye Drops, Gels, Iniectables. Infusion. Inhalation…

# NanoViricides Technology Platform Enables Multiple Potential Revenue Sources to Finance Future Growth

- **Potential Drug Licensing to Big Pharma :**
  - NV-387 Clinical Stage; NV-HHV-1 (Same Platform) IND-Enabled
- **Next Generation Drug ("Lifecycle Extension") and "Drug Rescue" Opportunities for Big Pharma :**
  - Example: NV-387-g-Rp Has Demonstrated that Encapsulating Remdesivir within NV-387 Improves Its Active Life in Bloodstream; AND Enables Oral Administration - Remdesivir Is Currently Only by Infusion
  - NV-387 Can Encapsulate Many Other Drugs to Provide Similar Benefits
  - Improvement in Drug Plasma Lifetime is a Critical Need
  - Making Injectables as Orally Available Drugs is a Critical Need
- **Biodefense and Pandemic Preparedness Applications :**
  - Smallpox New Drug Development is Sought
  - One Drug Treating Many Virus Families is Holy Grail of Pandemic Preparedness
- **Self-Commercialization in Smaller-Quantity Requiring Markets :**
  - RSV as well as Several Other Niche Markets Can be Captured by NanoViricides Using Our Own cGMP Manufacturing Capabilities

# NanoViricides Broad Pipeline Addressing Large Market Sizes to Fuel Continuing Growth Into the Future

- **NV-387, Clinical Stage Drug**
  - Several Billion Dollars Market Size for Coronaviruses Incl. SARS-CoV-2 and Long CoVID
    - Existing Drugs Have Several Limitations
  - $8 Billion Increasing to $20 Billion Estimated Market Size for RSV Treatment
    - No Current Treatment Except Highly Toxic Ribavirin; Recently Approved Antibodies and Vaccines Are Only Protective But Not Approved for Treatment
  - Multi-Billion Dollar Market Sizes for Treatment of Different Respiratory Viral Infections
  - NV-387 Alone Targets Overall Market Size in Excess of $20 Billion!
- **NV-HHV-1 and the HerpeCide™ Program -**
  - Billion Dollars Market Size for Treatment of Shingles Accounting for Shingrix Vaccine
  - Several Billion Dollars Market Size for Treatment of HSV-1 “Cold Sores” and HSV-2 “Genital Ulcers”. Also, Other Herpesviruses - CMV, EBV, HHV6A/6B
- **Drug Candidates For Over 40 Indications at Various Stages with Successful Pre-clinical Studies**
- **Antiviral Therapeutics Markets Estimated to be Over $65 Billion in 2023 and Increasing at double-digit CGA**
- **Markets Expand When an Effective Therapeutic Treatment Becomes Available**

# Summary

# Summary

- **Clinical Stage Pharma Company with Unique Nanomedicines Platform Technology**
- **Revolutionary Approach Resulting in Highly Effective and Exceedingly Safe Drugs**
- **Fully Integrated Pharma Company with Its Own R&D Labs, Nanomedicine Characterization Labs and c-GMP-Compliant Manufacturing Facility, Clean Rooms**
  - In-Process testing, QA/QC Analytical Lab, Bio-Analytical Lab, Cell Culture and BSL2 Virology Lab for Antiviral Assays are all On-Site in an 18,000+sq.ft. Facility
  - Well-equipped Facilities for All Tasks from Discovery, Syntheses, Scale-Up, c-GMP Manufacture of Various APIs, Different Drug products, Fill-Finish-Labeling and Packaging
- **Broad and Deep Pipeline Addressing Tens of Billions of Dollars in Market Sizes**
  - First Clinical Drug NV-387 with Multiple Indications; Also a Clinical-ready Drug, NV-HHV-1
  - Over 40 Indications Addressed to Date with Drug Candidates in Various Pre-Clinical Stages
- **Next Generation NanoViricides to Cure Most Virus Infections Already in Progress**
- **In-house cGMP Manufacture Enabling Early Commercial Revenues**
- **Major Regulatory Progress and Milestones to Occur Throughout Next Several Years**
- **Strong Asset Position**
- **Expert team**

# Strong Executive Team

## Anil R. Diwan, PhD
## President & Exec. Chairman

Co-Founder
Led Uplisting to NYSE-American Exchange in 2013
Raised Over $100M
Co-Inventor of Nanoviricides® & of TheraCour ®
25+ years Leadership & Entrepreneurial experience
Key Patents, Several NIH SBIR Awards
PhD (Biochem Eng - Rice), BTech (ChemEng - IITB)
Ranked 9th All India on JEE to IITs (1975)

## Krishna Menon, VMD, MRCS, PhD
## Consulting Pre-Clinical Studies

30+ Years of Pharmaceutical Industry Experience in Drug Discovery and Pre-clinical Regulatory Development
Eli Lilly President's Award

AZT, GemCitabine, Pemetrexed (Alimta) Development

Eli-Lilly, Dana-Farber, Beth-Israel, Bayer Alumnus

## Randall W. Barton, PhD
## Consulting CSO

30+ Years of Pharmaceutical Industry Experience in Drug Discovery and Pre-clinical Regulatory Development
Former Director of In-Vitro Cardiovascular Research at Boehringer Ingelheim

Nevirapine (Virammune™) Development

Visiting Faculty, UConn Medical School, Farmington, CT

## Meeta R. Vyas, MBA
## CFO

30+ years Experience in Corporate Performance Improvement, Finance, M&A, EBITDA Growth...
Previously: Principal, The Gores Group; Director, Kamylon Capital; CEO, Signature Brands, Inc. (a public company, known for "Mr. Coffee"); Ran $1B GE Appliances Division; Consultant, McKinsey & Company

MBA (Finance) Columbia U, BS (ChemEng) MIT

## Jayant Tatake, PhD
## VP, R&D

30+ Years of Pharmaceutical Industry Experience in Drug Discovery, Manufacturing, QA/QC, CRO, Synthesis, Scale-up, Formulations, and Pharmaceutical cGMP Expertise

Former Asst. Director, Pharma. Analytics, InterPharm, Inc.
Co-Inventor of Nanoviricides® & TheraCour®
PhD, UICT, Mumbai, India

# Board of Directors

## Anil R. Diwan, PhD
## President & Exec. Chairman

Co-Founder, Led Uplisting to NYSE-Amer. in 2013, Raised $100M+, Co-Inventor of Nanoviricides® & of TheraCour ® 30+ years Leadership & Entrepreneurial experience

**Not an Independent Board Member**
**Director and Chairman Since Founding in 2005**

## Mak Jawadekar, PhD ✔

35+ Years of Pharmaceutical Industry Experience, Pharma Strategic Consultant. Previously at Pfizer, Inc., as Director, Portfolio Management & Analytics, and as Vice President, Asia Colleague Resource Group, in Pfizer Global R&D. Business and Research experience in joint ventures, alliance management, contracting, pharma R&D, drug delivery, clinical supply manufacture, etc. Global experience working with United States, Europe, India, Japan, China.

**Independent Board Member since February, 2020**

## Hon'ble Theodore "Todd" Rokita, JD ✔

Presently Attorney General, State of Indiana. Former US Rep. from Indiana (4 terms since 2010). Served on several House Committees. Co-owner, Apex Benefits Group, Inc. Extensive executive, team-building, business strategy, and fiscal management expertise in the private sector, alongside his public service leadership experience. Serves or has served as a Member of the Board of Directors of several commercial and charitable institutions.

**Independent Board Member since May, 2020**

## Brian M. Zucker, CPA ✔

30+ years of experience as a CPA specializing in the securities industry. A Partner at CFO Financial Partners, LLC (https://www.cfopartners.com/). Also serves as the CFO and Financial Operations Principal for numerous broker dealers and hedge funds. Partner at RRBB Accountants & Advisors. CFO of EIG Energy Partners Capital Markets, LLC. Ex-Senior Consultant at Deloitte Haskins & Sells and at Price Waterhouse. Mr. Zucker holds several FINRA licenses.

**Independent Board Member since November, 2020**

✔ = Independent Board Member

# Together We Can Destroy Viruses



# Thank you for your attention.